Actelion’s Lung Drug May Face Study Against Gilead Rival

Actelion Ltd.’s Opsumit may face a clinical trial comparing its effectiveness with Gilead Sciences Inc.’s lung drug Letairis, potentially threatening the treatment’s predicted dominance.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.